{
    "organizations": [],
    "uuid": "faca86855c292a61f7d3666435e47e27be455814",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bavarian-nordic-announces-phase-2/brief-bavarian-nordic-announces-phase-2-trial-investigating-combination-of-its-immunotherapy-cv301-and-nivolumab-in-microsatellite-stable-colorectal-cancer-idUSASB0C9H0",
    "ord_in_thread": 0,
    "title": "BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Market News March 8, 2018 / 2:11 PM / Updated 5 minutes ago BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer Reuters Staff 1 Min Read March 8 (Reuters) - Bavarian Nordic A/S: * BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER * BAVARIAN NORDIC A/S - CO, ‍BRISTOL-MYERS SQUIBB AGREE TO SUPPLY CLINICAL MATERIAL FOR TRIAL​ * BAVARIAN NORDIC A/S - ‍PHASE 2 RANDOMIZED TRIAL WILL ENROLL UP TO 74 PATIENTS​ Source text for Eikon: Further company coverage:",
    "published": "2018-03-08T16:11:00.000+02:00",
    "crawled": "2018-03-08T16:21:43.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "market",
        "news",
        "march",
        "pm",
        "updated",
        "minute",
        "ago",
        "nordic",
        "announces",
        "phase",
        "trial",
        "investigating",
        "combination",
        "immunotherapy",
        "cv301",
        "nivolumab",
        "microsatellite",
        "stable",
        "colorectal",
        "cancer",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "bavarian",
        "nordic",
        "bavarian",
        "nordic",
        "announces",
        "phase",
        "trial",
        "investigating",
        "combination",
        "immunotherapy",
        "cv301",
        "nivolumab",
        "microsatellite",
        "stable",
        "colorectal",
        "cancer",
        "bavarian",
        "nordic",
        "co",
        "squibb",
        "agree",
        "supply",
        "clinical",
        "material",
        "bavarian",
        "nordic",
        "randomized",
        "trial",
        "enroll",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}